Blueshift Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Blueshift Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,722	Closed	-$257K	–	1178
2021 Q4	$257K	Buy	+15,722	New	+$262K	0.02%	682
2021 Q2	–	Sell	-15,731	Closed	-$440K	–	1224
2021 Q1	$440K	Buy	+15,731	New	+$435K	0.05%	511

Other funds holding RVNC

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Blueshift Asset Management's RVNC Position: Q1 2022 in Review

Blueshift Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2022, closing a stake of 15,722 shares — an estimated $257K sold.

Blueshift Asset Management first reported a position in RVNC in Q1 2021 and held it in 2 quarters. The position peaked at $440K in Q1 2021. 156 funds tracked by Wall St. Rank hold RVNC as of Q1 2022.

Blueshift Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
Blueshift Asset Management sold 15,722 Revance Therapeutics, Inc. shares in Q1 2022, an estimated $257K.
Blueshift Asset Management first reported a position in Revance Therapeutics, Inc. in Q1 2021 and held it in 2 quarters.
Blueshift Asset Management's Revance Therapeutics, Inc. position peaked at $440K in Q1 2021.
156 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2022.

Based on Blueshift Asset Management's 13F filing for Q1 2022, filed 12 May 2022.